Ontario Teachers Pension Plan Board trimmed its position in shares of Omnicell, Inc. (NASDAQ:OMCL – Free Report) by 47.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,187 shares of the company’s stock after selling 17,024 shares during the quarter. Ontario Teachers Pension Plan Board’s holdings in Omnicell were worth $561,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Connors Investor Services Inc. boosted its holdings in Omnicell by 64.6% during the 1st quarter. Connors Investor Services Inc. now owns 95,547 shares of the company’s stock valued at $2,793,000 after acquiring an additional 37,502 shares during the period. Vanguard Group Inc. raised its position in Omnicell by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,651,732 shares of the company’s stock valued at $165,200,000 after purchasing an additional 80,312 shares in the last quarter. State Board of Administration of Florida Retirement System raised its position in Omnicell by 14.3% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 14,660 shares of the company’s stock valued at $429,000 after purchasing an additional 1,830 shares in the last quarter. Entropy Technologies LP acquired a new stake in Omnicell in the 1st quarter valued at about $227,000. Finally, ProShare Advisors LLC raised its position in Omnicell by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after purchasing an additional 626 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the company. Benchmark reaffirmed a “buy” rating and issued a $38.00 price target on shares of Omnicell in a research report on Monday, July 15th. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $42.20.
Omnicell Stock Performance
OMCL traded up $0.52 during trading on Monday, hitting $28.04. 353,787 shares of the stock were exchanged, compared to its average volume of 519,670. The firm has a market capitalization of $1.29 billion, a P/E ratio of -59.83, a PEG ratio of 97.59 and a beta of 0.80. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $66.65. The stock has a fifty day moving average price of $28.87 and a two-hundred day moving average price of $29.27. The company has a quick ratio of 2.13, a current ratio of 2.38 and a debt-to-equity ratio of 0.48.
Omnicell (NASDAQ:OMCL – Get Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.17. The company had revenue of $246.15 million for the quarter, compared to analyst estimates of $235.70 million. Omnicell had a positive return on equity of 2.41% and a negative net margin of 1.91%. As a group, sell-side analysts predict that Omnicell, Inc. will post 0.2 earnings per share for the current year.
Omnicell Company Profile
Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.
See Also
- Five stocks we like better than Omnicell
- How Can Investors Benefit From After-Hours Trading
- Intuitive Surgical Stock Outperforms Market: Highs on the Horizon
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Has This Leading Tech Stock Halted the AI Surge?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Revolutionary Battery Stock Gains Momentum with 3D Silicon-Anodes
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.